NEI Research News

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

Los investigadores determinaron que los latinos presentan mayores índices de deterioro visual, ceguera, enfermedad diabética del ojo y cataratas que los blancos no hispanos.

Latinos have higher rates of developing visual impairment, blindness, diabetic eye disease, and cataracts than non-Hispanic whites, researchers found. These are the first estimates of visual impairment and eye disease development in Latinos.

Researchers have shown that ranibizumab eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.

A large genetic study of age-related macular degeneration (AMD) has identified three new genes associated with this blinding eye disease-two involved in the cholesterol pathway.

Scientists have shown that through an eye exam, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity (ROP), resulting in better vision for many children

The National Eye Institute mourns the loss of M. Velma Dobson, Ph.D., a long-time advisor and expert on NEI clinical research studies in infants and children. She passed away on Friday, April 9 from Lou Gehrig’s disease.

A National Eye Institute (NEI) study found that the prevalence of myopia, or nearsightedness, increased 66 percent in the United States between 1971-1972 and 1999-2004.

NEI support leading to gene therapy clinical trials for people with Leber congenital amaurosis (LCA) consisted of significant efforts by investigators in the intramural laboratories at the NEI.

Three young adults with an inherited form of blindness showed evidence of improved day and night vision following a specialized gene transfer procedure in a phase 1 clinical trial funded by the National Eye Institute (NEI), part of the NIH.